TRPC6: an underlying target for human glaucoma
Author:
Contact Author:

Affiliation:

Clc Number:

Fund Project:

National Natural Science Foundation of China (No. 81170849); Guangdong Provincial Natural Science Foundation, China (No. S2011020002401); Research Fund for the Doctoral Program of Higher Education of China (RFDP, 20100171110077)

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    Glaucoma is one of the leading causes of visual impairment and blindness worldwide. Of known risk factors for glaucoma, an increased in intraocular pressure is most highly correlated with glaucomatous damage. Irrespective of the cause, apoptosis of the retinal ganglion cells is the eventual outcome. It is widely accepted that glaucoma is a neurodegenerative disease that is strongly correlated with central nervous system disorders, such as Alzheimer’s disease. These two disorders also share some similarities in pathogenic mechanisms. Recent studies suggest that the transient receptor potential canonical 6 channel could work together with brain-derived neurotrophic factor to promote neuron survival in brain and retina. In this study, we propose that transient receptor potential canonical 6 may contribute to the pathogenesis of human glaucoma and become a potential therapeutic target.

    Reference
    Related
    Cited by
Get Citation

Qian Fan, Wen-Bin Huang, Xiu-Lan Zhang. TRPC6: an underlying target for human glaucoma. Int J Ophthalmol, 2012,5(4):523-526

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:February 12,2012
  • Revised:July 20,2012
  • Adopted:
  • Online:
  • Published: